Saturday, April 4, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

FDA could authorize COVID shots for children under 5 in June

The Food and Drug Administration could authorize a Covid-19 vaccine for children under age 5 in June, according to two people familiar with the plans.

The agency has asked members of its advisory panel, called the Vaccines and Related Biological Products Advisory Committee, to set aside several days in June to potentially meet, the people said.

The panel members haven’t been told what the tentative meeting will be about, but it’s presumed the discussion will involve the topic of vaccinations in the nation’s youngest cohort, one of the people said. The first potential meeting date is June 1.

The days are still subject to change, the people said, especially if the trajectory of the Covid cases continues to rise in the United States.

The FDA had also tentatively scheduled meetings of the advisory committee in May, but those were eventually scrapped.

There are an estimated 19.5 million children under age 5 in the U.S. and Puerto Rico, according to NBC News data.

Kids under 5 are the only group in the U.S. ineligible to receive a Covid vaccine, but efforts to vaccinate this age group have been met with delays.

Source: NBC News

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide and the Expansion Problem: When One Trial Becomes a Platform

Semaglutide has moved beyond its original indication and now sits at the center of a widening set of clinical questions: cardiovascular risk, kidney disease progression, and even neurodegeneration. The question is no longer whether the drug lowers glucose or reduces weight—it does—but how far those effects extend across systems, and whether evidence from one population can be translated into another without distortion. Large, well-powered trials have produced consistent signals, yet those signals are now being applied in contexts that were...

Read more

Join Our Newsletter!